Claims
- 1. A compound represented by Formula I:
- 2. The compound of claim 1, wherein the polymer chain comprises n′ units of U, wherein n′ represents an integer in the range of 1 to about 30,000; and U is represented by the general formula:
- 3. A compound represented by Formula II:
- 4. A compound represented by Formula III:
- 5. The compound of any of claims 1-4, wherein the linker group represents a hydrocarbylene group wherein one or more methylene groups is optionally replaced by a group Y (provided that none of the Y groups are adjacent to each other), wherein each Y, independently for each occurrence, is selected from, substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, or —O—, C(═X) (wherein X is NR1, O or S), —OC(O)—, —C(═O)O, —NR1—, —NR1CO—, —C(O)NR1—, —S(O)n— (wherein n is 0, 1, or 2), —OC(O)—NR1, —NR1—C(O)—NR1—, —NR1—C(NR1)—NR1—, and —B(OR1)—; and R1, independently for each occurrence, represents H or a lower alkyl.
- 6. The compound of any of claims 1-4, wherein the linker group represents an amino acid or peptide, or derivative thereof.
- 7. The compound of any of claims 1-4, wherein said therapeutic agent is a small molecule, a peptide, a protein or a polymer that has therapeutic activity.
- 8. The compound of any of claims 1-4, wherein the therapeutic agent is hydrophobic (log P>0.4, 0.6, 0.8, 1).
- 9. The compound of any of claims 1-4, wherein the therapeutic agent has low aqueous solubility.
- 10. The compound of any of claims 1-4, wherein therapeutic agent or targeting ligand is covalently-bonded to the linker group via biohydrolyzable bond.
- 11. The compound of claim 10, wherein the biohydrolyzable bond is selected from an ester, amide, carbonate, or a carbamate.
- 12. The compound of any of claims 1-4, wherein therapeutic agent is selected from an anti-cancer, anti-fungal, anti-bacterial, anti-mycotic, or anti-viral therapeutic.
- 13. The compound of any of claims 1-4, wherein the therapeutic agent is a receptor agonist.
- 14. The compound of any of claims 1-4, wherein the therapeutic agent is a receptor antagonist.
- 15. The compound of any of claims 1-4, wherein the compound is biodegradable or bioerodable.
- 16. The compound of any of claims 1-4, wherein the compound has a number average (Mn) molecular weight between 1,000 to 500,000 amu.
- 17. The compound of any of claims 1-4, wherein the polymer has a number average (Mn) molecular weight between 5,000 to 200,000 amu.
- 18. The compound of any of claims 1-4, wherein the polymer has a number average (Mn) molecular weight between 10,000 to 100,000 amu.
- 19. A pharmaceutical preparation comprising a pharmaceutical excipient and a compound of any of claims 1-4, or a pharmaceutically acceptable ester, salt, or hydrate thereof.
- 20. A pharmaceutical dosage form comprising of a therapeutically effective amount of one or more of the compounds of any of claims 1-4.
- 21. A method for treating an animal comprising administering a therapeutically effective amount of one or more of the compounds of any of claims 1-4.
- 22. A method for conducting a pharmaceutical business, comprising:
a. manufacturing a formulation or kit including a pharmaceutical composition of any of the compounds of claim 1, 2, 3, or 4; and b. marketing to healthcare providers the benefits of using the formulation or kit in the treatment of a disease or disorder.
- 23. A method for conducting a pharmaceutical business, comprising:
a. providing a distribution network for selling a pharmaceutical composition of any of the compounds of claim 1, 2, 3, or 4; and b. providing instruction material to patients or physicians for using the preparation in the treatment of a disease or disorder.
- 24. A method for conducting a pharmaceutical business, comprising:
a. determining an appropriate formulation and dosage of a pharmaceutical composition of any of the compounds of claim 1, 2, 3, or 4; b. conducting therapeutic profiling of formulations identified in step (a), for efficacy and toxicity in animals; and c. providing a distribution network for selling a preparation or preparations identified in step (b) as having an acceptable therapeutic profile.
- 25. The method of claim 24, including an additional step of providing a sales group for marketing the preparation to healthcare providers.
- 26. A method for conducting a pharmaceutical business, comprising:
a. determining an appropriate formulation and dosage of a pharmaceutical composition of any of the compounds of claim 1, 2, 3, or 4; and b. licensing, to a third party, the rights for further development and sale of the formulation.
- 27. A method of preparing the compound of claim 1, 2, 3, or 4.
- 28. A modified cyclodextrin ring, wherein exactly two hydroxyl moieties are replaced by a nitrogen or sulfur atom of an amino acid.
- 29. A modified cyclodextrin ring of claim 28, wherein the amino acid is an alpha-mino acid.
- 30. A modified cyclodextrin ring of claim 29, wherein the amino acid is cysteine, tryptophan, glutamic acid, aspartic acid, lysine, arginine, histidine, or arginine.
- 31. A modified cyclodextrin ring of claim 28, wherein the amino acid is included in an oligopeptide comprising 2 to 50 amino acid residues.
- 32. A modified cyclodextrin ring of claim 31, wherein the oligopeptide comprises 230 amino acid residues.
- 33. A modified cyclodextrin ring of claim 31, wherein the oligopeptide comprises 215 amino acid residues.
- 34. A linear, water-soluble, cyclodextrin-containing polymer, wherein a plurality of bioactive moieties are covalently attached to the polymer through attachments that are cleaved under biological conditions to release the bioactive moieties, wherein administration of the polymer to a patient results in release of the bioactive agent.
- 35. The compound of any of claims 1-4, wherein therapeutic agent is selected from anorexics, antiarthitics, artiasthmatic agents, anticonvuisants, antidepressants; antihistamines, anti-inflammatory agents, antinauseants, antineoplastics, antipruritics, antipsychotics, antipyretics, antispasmodics, cardiovascular preparations, antihypertensives, diuretics, vasodilators, central nervous system stimulants, cough and cold preparations, decongestants, diagnostics, hormones, bone growth stimulants and bone resorption inhibitors, immunosuppressives, muscle relaxants, psychostimulants, sedatives, tranquilizers, anti-inflammatory agents, anti-epileptics, anesthetics, hypnotics, sedatives, neuroleptic agents, antidepressants, anxiolytics, anticonvulsant agents, neuron blocking agents, anticholinergic and cholinomimetic agents, antimuscarinic and muscarinic agents, antiadrenergics, antiarrhythmics, and antihypertensive agents.
RELATED APPLICATIONS
[0001] This patent application claims the benefit of U.S. Provisional Application No. 60/408,855 filed on Sep. 6, 2002, No. 60/422,830 filed on Oct. 31, 2002, and No. 60/451,998 filed on Mar. 4, 2003. The specifications of these three applications are incorporated herein by reference in their entirety.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60408855 |
Sep 2002 |
US |
|
60422830 |
Oct 2002 |
US |
|
60451998 |
Mar 2003 |
US |